Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences (Nasdaq: SLDB) granted 8,070 restricted stock units (RSUs) to a newly hired employee on May 1, 2026 as an inducement under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) granted 8,070 restricted stock units (RSUs) to a newly hired employee on May 1, 2026 as an inducement under Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments through the fourth anniversary, subject to continued service, under the 2024 Inducement Stock Incentive Plan.

Argus May 4 session

+1.40% close to close Open Argus

Details

News Market Reaction – SLDB

On May 4, the first trading day after this news, SLDB closed 1.40% above the previous close.

Data tracked by StockTitan Argus for the May 4 session.

Key Figures

RSU grant: 8,070 RSUs Vesting schedule: 4 equal installments Registered shares: 42,780,739 shares +5 more

RSU grant

8,070 RSUs

Inducement award to one newly hired employee under 2024 Inducement Plan

Vesting schedule

4 equal installments

Annual vesting on each one-year anniversary through year four

Registered shares

42,780,739 shares

Common stock registered for resale under effective S-3 filed 2026-03-19

Private placement proceeds

$240.0 million

Gross proceeds from March 2026 private placement

Shares outstanding

98,391,314 shares

Common shares outstanding as of March 10, 2026

Current price

$7.26

Pre-news price with 24h change of 2.98%

52-week range

$2.41–$8.8661

Current price 201.24% above low and 18.12% below high

Pre-funded warrant shares

27,807,482 shares

Shares issuable upon exercise of pre-funded warrants in March 2026 deal

Historical Context

5 past events · Latest: Apr 30

5 events

1. Apr 30

   Scientific conference plans

   24h Move

   +3.0%

   Announced largest scientific program with 16 ASGCT presentations in May 2026.

2. Apr 28

   Regulatory designation

   24h Move

   -0.7%

   EC granted Orphan Drug designation for SGT-003 in Duchenne muscular dystrophy.

3. Apr 07

   Investor conferences

   24h Move

   +0.0%

   Planned participation in Needham and Piper Sandler investor events in April 2026.

4. Mar 19

   Earnings and update

   24h Move

   -1.3%

   Reported Q4/FY25 results, pipeline progress, $187.9M cash and $240M private placement.

5. Mar 11

   Clinical trial update

   24h Move

   -5.7%

   Interim positive data from Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 with 40 dosed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), inducement stock incentive plan

3 terms

restricted stock units financial

"announced a grant of 8,070 restricted stock units (“RSUs”) to one newly hired employee"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"pursuant to the Company’s 2024 Inducement Stock Incentive Plan"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHARLESTOWN, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,070 restricted stock units (“RSUs”) to one newly hired employee.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Senior Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What RSU grant did Solid Biosciences (SLDB) announce on May 1, 2026?

The company granted 8,070 restricted stock units to a newly hired employee as an inducement. According to company, the RSUs were issued under the 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).

How do the 8,070 RSUs for SLDB vest and when are the vesting dates?

The RSUs vest in four equal annual installments, one each year through the fourth anniversary. According to company, each installment vests on the one-year anniversary of the grant date, subject to continued service through each vesting date.

Why did Solid Biosciences (SLDB) use Listing Rule 5635(c)(4) for the RSU grant?

The grant was made as an inducement material to the employee’s acceptance of employment. According to company, using Nasdaq Listing Rule 5635(c)(4) permits grants outside existing shareholder-approved plans for new-hire inducements.

Does the May 1, 2026 RSU grant for SLDB create immediate dilution for shareholders?

The announcement does not quantify immediate dilution or share count impact. According to company, 8,070 RSUs were granted, but no total outstanding share or dilution figure was provided in the disclosure.